Nitric oxide (NO) generated by inducible NO synthase (iNOS) plays crucial roles in inflammation and host defense. With an intrinsically bound calmodulin, iNOS is fully active once expressed in cells. Thus, regulation of NO production from iNOS was thought to primarily occur at enzyme transcriptional level. Here we show that NO synthesis from iNOS can be profoundly modulated by heat shock protein 90 (hsp90) through protein-protein interaction. To study whether hsp90 affects iNOS function, recombinant murine iNOS was purified from an E. coli expression system by affinity chromatography. Hsp90, at physiological concentrations (10-500 nM), dose-dependently increased iNOS activity. This was a specific effect because neither denatured hsp90 nor irrelevant bovine serum albumin affected iNOS function. Overexpression of hsp90 enhanced NO production in iNOS-transfected cells. On the contrary, hsp90 inhibition dramatically decreased NO formation from iNOS in macrophages. Co-immunoprecipitation studies showed that hsp90 and iNOS associated each other in cells. Overexpression of iNOS resulted in NO-mediated cellular injury. Hsp90 inhibition markedly attenuated NO formation and prevented cellular injury. These results demonstrated that hsp90 is an allosteric enhancer of iNOS. iNOS is coupled with hsp90 in cells and this coupling facilitates NO synthesis. In light of the critical role of hsp90 in iNOS-mediated cytotoxic action, modulating the interaction between hsp90 and iNOS may be a new approach to intervene inflammation and immune response.
Co-immunoprecipitation
Cells were lysed on ice in the following lysis buffer: 50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 0.5 % NP-40, 1 mM EDTA, 10 % glycerol, and protease inhibitor tablet (Roche). After centrifugation (16,000g for 30 min, 4 ºC), the supernatants were pooled and incubated with 2 µg primary antibodies overnight at 4 ºC. The immunoprecipitates were harvested by protein A/G-agarose beads (Santa Cruz). After extensive washing, immunoprecipitates were eluated by 5 min boiling of the beads in SDS/PAGE sample buffer (62.5 mM Tris-HCl, pH 6.8, 2 % SDS, 40 mM DTT, and 10 % glycerol) and characterized by Western blotting with appropriate antibodies.
Western blotting
Harvested cells were lysed in RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1%
NP-40, 0.1% SDS, 0.25% n-octyl ß-D-glucopyranocide, and protease inhibitor tablet) on ice for 40 min. After a brief centrifugation (16,000g for 5 min), the protein concentrations of the lysates were determined using Bio-Rad DC protein assay kit. Samples were electrophoresed on 4 -12% polyacrylamide gels, transferred to nitrocellulose membranes, and probed with anti-iNOS polyclonal or anti-HSP90 monoclonal antibodies (Transduction Laboratories). Immunoblots were developed on films using the enhanced chemiluminescence technique (ECL, Amersham).
EPR spectroscopy and spin trapping
EPR measurements of NO were performed on 10 7 cells in phosphate-balanced buffer using the iron complex of DETC [Fe
3+
-(DETC) 2 , Fe-DETC, 0.5 mM] as spin trap (18) . EPR spectra were recorded in a quartz flat cell at room temperature (23 o C) with a Bruker ER 300 spectrometer operating at X-band with a TM110 cavity using a modulation frequency of 100 kHz, modulation amplitude of 0.5 G, microwave power of 20 mW, and microwave frequency of 9.785 GHz. The microwave frequency and magnetic field were precisely measured using an EIP 575 microwave frequency counter and Bruker ER 035 NMR gaussmeter. NO signals were quantitated by double integration as previously described (18) .
Nitrite/nitrate and cell viability assays
Total nitrate and nitrite released in cell culture medium was measured by a nitrite/nitrate colorimetric assay kit (Cayman Chemical). Cell viability was monitored by MTT assay (26) . COS-7 cells transfected with iNOS vector were cultured in the absence and presence of hsp90 inhibitor or NOS inhibitor for 24 hr. To evaluate iNOS-mediated cytotoxicity in macrophages, RAW264.7 cells were stimulated with LPS (2 µg/ml) and IFN-γ (100 units/ml) for 16 hr. Then cells were incubated with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 5 mg/ml) for 1 hr at 37 ºC and solubilized by 1% SDS solution containing 10 mM HCl. The reduced MTT was determined by measuring the absorbance at 570 nm using a Cary 50 spectrophotometer.
Statistics
Data were expressed as Mean ± S.E. Comparisons were made using a two-tailed Student's paired or unpaired t-test. Differences were considered to be statistically significant at P < 0.05.
RESULTS
We first determined the effect of hsp90 on iNOS function in vitro using purified enzyme preparations. Recombinant murine iNOS was isolated from an E. coli expression system by affinity chromatography. The purity and catalytic activity of the iNOS preparations were characterized ( Fig. 1) . Purified iNOS displayed as a single band on SDS/PAGE with a molecular mass of 130 kDa, which was in agreement with the molecular mass of native iNOS reported previously (3) (4) (5) . Purified enzyme preparations exhibited strong L- Neither geldanamycin nor radicicol treatment affected iNOS and hsp90 expression levels in cells (Fig. 4D ). These data indicated that normal hsp90 function was needed for iNOS-catalyzed NO synthesis in macrophages.
To explore whether hsp90 and iNOS can physically associate each other, immunoprecipitations of iNOS were carried out on both control and LPS/IFN-γ stimulated RAW 264.7 cells. Although both control and stimulated cells contained the same levels of hsp90, immunoprecipitation of iNOS resulted in a co-precipitation of hsp90 in stimulated cells but not in control cells (Fig. 5A) . Similarly, immunoprecipitation of hsp90 also co-precipitated iNOS in stimulated cells but not in control non-stimulated cells (Fig. 5B ). These findings suggested that iNOS coupled with hsp90 in macrophages.
To determine the functional significance of the hsp90-iNOS interaction, we studied the roles of hsp90 in iNOS-mediated cytotoxicity. iNOS was transfected into COS-7 cells and NO production was measured and correlated with the alterations of cell viability. As shown in Fig. 6 , control non-transfected COS-7 cells produced little NO and displayed normal viability. Robust NO formation was detected from the cells after iNOS transfection. Correspondingly, significant amounts of cells were damaged (65.1 ± 3.3% cell viability, P<0.001 compared with control cells, n=12). Treating the cells with hsp90 inhibitor radicicol markedly inhibited NO formation. As a result, cell injury was largely prevented (89 ± 4.6% cells viable). The classic NOS inhibitor L-NAME (500 µM) also blocked NO formation and protected cells. Neither radicicol nor L-NAME changed the levels of iNOS expressed in cells. These results demonstrated that normal hsp90 function was required in the cytotoxic action of iNOS.
Finally, we determined the role of hsp90 in controlling iNOS-mediated cytotoxicity in macrophages. As shown in Fig. 7 , induction of iNOS expression by LPS/IFN-γ caused a significant cellular injury (57 ± 1.5% cell viability, P<0.001, n=6). Both hsp90 inhibitor radicicol (5 µM) and NOS blocker L-NAME (1 mM) prevented this cellular damage (94.8 ± 3.6% and 92.2 ± 5.6% cell viability, respectively, n=6). These data strongly indicated that hsp90 played an essential role in iNOS-mediated cytotoxicity in inflammation.
DISCUSSION
The key finding of the present study was that hsp90 enhanced iNOS catalytic function.
With an intrinsically bound CaM, iNOS was believed to constantly exhibit full activity once expressed. Since cytosolic L-arginine concentrations (100-800 µM) are at least ten times higher than the Km of L-arginine to iNOS (1-10 µM) (4, 27) , NO production from iNOS pathway was thought to be determined by the quantity of iNOS protein. The present study identified hsp90 as a novel protein modulator which can fundamentally influence NO production from iNOS. Hsp90 is known as one of the most abundant cytosolic proteins in eukaryotic cells under normal conditions (28). In most cells, hsp90 was estimated to account for 1-2% of total cellular protein and may reach micromole intracellular concentrations. Under stress conditions, its expression level can further increase several fold (29). Our in vitro measurements showed that hsp90 enhanced iNOS activity at its physiological concentration range. With the presence of 500 nM hsp90, iNOS activity increased more than two fold. This increase was quite unexpected because iNOS was previously thought to always function at its maximal efficacy. Thus, iNOS function can be modulated by posttranslational interaction with hsp90. These findings also suggested that in addition to enzyme quantity, the overall NO production from iNOS will be profoundly influenced by the levels and function status of cytosolic hsp90.
Indeed, overexpression of hsp90 markedly increased NO formation in iNOS-transfected cells. More importantly, in LPS/IFN-γ induced macrophages, hsp90 inhibition with both geldanamycin and radicicol markedly attenuated NO production. These findings indicated that NO production in inflammation was not a sole action of iNOS but a result of iNOS-hsp90 interaction.
Since hsp90 inhibition has been reported to cause degradation of its client proteins such as Raf, HER2, and mutant p53 (30-32), possible questions may be raised concerning whether the decreased NO formation was due to lose of iNOS protein after hsp90 blocker treatment. This possibility was ruled out by the control experiments which showed that brief exposure of cells to geldanamycin or radicicol did not change the levels of iNOS expression. Thus, the decrease in NO formation was caused by the inhibition of hsp90 function. Geldanamycin and radicicol are two structurally different hsp90 inhibitors (32). Geldanamycin was reported to redox cycle with flavincontaining enzymes to form superoxide which can subsequently inactivate NO (33). But the nonquinone hsp90 inhibitor radicicol is redox insensitive (34). Moreover, parallel to the decrease of NO production, L-citrulline formation inside cells was also reduced in hsp90 inhibitor-treated cells. These data reconfirmed that the decrease of NO production was due to declined iNOS activity rather than inactivation by superoxide.
Hsp90 has been shown to facilitate eNOS and nNOS function. Two possible mechanisms have been proposed to account for the effect of hsp90 on nNOS. One study reported that hsp90 functioned as a chaperon to facilitate heme insertion during nNOS assembly (16) . Other studies showed that hsp90 augmented nNOS activity by enhancing CaM binding affinity (17, 18) . Neither of these two mechanisms is likely applicable to the effect of hsp90 on iNOS because the iNOS used in this study was already assembled with heme and possessed a bound CaM. In addition to acting as an allosteric regulator, recent studies showed that hsp90 also served as a module to recruit Akt to phosphorylate eNOS leading to increased enzymatic activity (15) . Our in vitro experiments were carried out with purified hsp90 and iNOS, which pre-excluded the involvement of other proteins such as kinases. The enhancement of enzyme catalysis was therefore the result of direct interaction between nNOS and hsp90. Though the exact molecular mechanism underlying the effect of hsp90 on iNOS remains to be uncovered, certain possibilities may be considered in light of the functional roles of hsp90 in other well-characterized systems. Known as a molecular chaperone, hsp90 not only participates in protein refolding process but also assists in the maintenance of correct protein conformation (35-37). It is conceivable that the interaction with hsp90 may keep iNOS in a conformation facilitating NO synthesis.
Both iNOS and hsp90 are cytosolic proteins. The co-immunoprecipitation studies suggested that iNOS associated with hsp90 in cells. The exact region of iNOS responsible for hsp90 binding remains to be determined. A recent study using both co-immunoprecipitation and yeast two-hybrid analysis revealed that hsp90 binding domain of eNOS located between amino acids 300-400 (15) . We compared the sequences of iNOS and eNOS and found that the sequence between iNOS residues 337 to 407 shares 70% identity with that in the region of eNOS amino acids 329-399 (Fig. 5C ). We speculate that this region of iNOS is responsible for hsp90 binding.
Experiments using a series of deletion mutants of iNOS are undergoing to examine this hypothesis. This region locates within the iNOS oxygenase domain where heme binds and NO synthesis takes place. Interacting with hsp90 may render iNOS oxygenase domain in a conformation with enhanced enzyme turnover efficacy.
NO is toxic molecule and large amounts of NO formation from iNOS is a fundamental host defense mechanism in biological system. NO production from iNOS has also been demonstrated to play important roles in the pathogenesis of cell injury in various inflammatory diseases (1) (2) (3) 20) . It was previously thought that NO-mediated cell injury in inflammation or immune responses was largely dependent on quantity and activity of iNOS. The present study provided the first evidence demonstrating that hsp90 also played a crucial role in iNOS-mediated cytotoxicity. In iNOS-transfected cells, inhibition of hsp90 function decreased iNOS function and prevented cell injury. Furthermore, hsp90 inhibition also abolished iNOS-mediated cytotoxicity in macrophages. These results are consistent with the findings from purified enzyme and cells and suggest that hsp90 is an important modulator that controls the cytotoxic action of iNOS in inflammation and immune responses.
In summary, the present study has identified hsp90 as an important endogenous protein enhancer of iNOS. Hsp90 associated with iNOS in cells and this association facilitated NO synthesis. Since hsp90 plays a pivotal role in the cytotoxic effect of iNOS, intervening hsp90 function may be a new approach to modulate iNOS function in inflammation and immune defense. and 10 nM iNOS in the absence (control) and presence of hsp90 (10-500 nM). As shown, hsp90 dosedependently augmented iNOS activity. In contrast, neither heat denatured hsp90 (500 nM) nor the irrelevant protein BAS (500 nM) affected iNOS activity (Mean ± S.E.; ***, P<0.001, compared with control, n=6). 
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